What’s Next for Allergan Plc Ordinary Shares (NYSE:AGN) After Having More Shares Shorted?

April 17, 2018 - By Vivian Currie

Allergan plc (NYSE:AGN) Logo

Investors sentiment increased to 1.25 in Q4 2017. Its up 0.92, from 0.33 in 2017Q3. It improved, as 2 investors sold Allergan plc shares while 2 reduced holdings. 1 funds opened positions while 4 raised stakes. 44,210 shares or 18.56% less from 54,287 shares in 2017Q3 were reported.
Eqis Cap Mngmt accumulated 10,789 shares or 0.09% of the stock. Frontier Mgmt has invested 0.2% in Allergan plc (NYSE:AGN). Callahan Advisors Limited Liability Company holds 4,500 shares or 0.15% of its portfolio. Gemmer Asset Mgmt Limited Com accumulated 214 shares. Grassi Inv Management holds 0.2% or 7,435 shares. Rech And Management invested 0% of its portfolio in Allergan plc (NYSE:AGN). Cubic Asset Management Ltd Limited Liability Company has invested 0.11% in Allergan plc (NYSE:AGN). Mitchell Mcleod Pugh Williams holds 3,965 shares.

The stock of Allergan Plc Ordinary Shares (NYSE:AGN) registered an increase of 9.83% in short interest. AGN’s total short interest was 7.02M shares in April as published by FINRA. Its up 9.83% from 6.39 million shares, reported previously. With 3.00M shares average volume, it will take short sellers 2 days to cover their AGN’s short positions. The short interest to Allergan Plc Ordinary Shares’s float is 2.23%.

The stock increased 0.64% or $1.06 during the last trading session, reaching $167.51. About 601,106 shares traded. Allergan plc (NYSE:AGN) has declined 33.03% since April 17, 2017 and is downtrending. It has underperformed by 44.58% the S&P500.

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The company has market cap of $54.87 billion. It operates through US Specialized Therapeutics, US General Medicine, and International divisions. It currently has negative earnings. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womenÂ’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as AlzheimerÂ’s disease.

Allergan plc (NYSE:AGN) Ratings Coverage

Among 18 analysts covering Allergan (NYSE:AGN), 13 have Buy rating, 0 Sell and 5 Hold. Therefore 72% are positive. Allergan had 32 analyst reports since October 18, 2017 according to SRatingsIntel. On Wednesday, December 6 the stock rating was maintained by Wells Fargo with “Buy”. The rating was downgraded by Mizuho to “Neutral” on Thursday, October 19. The stock of Allergan plc (NYSE:AGN) has “Buy” rating given on Wednesday, January 10 by UBS. The stock of Allergan plc (NYSE:AGN) has “Overweight” rating given on Wednesday, November 29 by Morgan Stanley. The stock has “Buy” rating by RBC Capital Markets on Thursday, October 19. The firm earned “Hold” rating on Tuesday, February 6 by Piper Jaffray. The stock of Allergan plc (NYSE:AGN) has “Outperform” rating given on Monday, November 27 by Leerink Swann. The rating was maintained by Citigroup on Thursday, October 19 with “Buy”. Susquehanna maintained it with “Hold” rating and $195.0 target in Wednesday, January 17 report. The rating was maintained by Mizuho on Tuesday, February 6 with “Hold”.

Allergan plc (NYSE:AGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: